In another pan-cancer study, researchers found discordance between HER2 copy number variation, mRNA expression, and protein expression level in colorectal and serous endometrial cancer [44], which demonstrates that a simple protein-based analysis of patients’ samples across tumor subtypes could highlight potential therapeutic targets. The gene discussed is ERBB2; the disease is cancer.